BioCorRx to Participate in the Benzinga All Access Event on December 2nd
November 24, 2021 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx Acquires Intellectual Property for Drug Delivery
November 22, 2021 09:15 ET
|
BioCorRx Inc
Patent Application Covers Solid Implant Formulation for Drug Delivery ANAHEIM, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
BioCorRx Provides Business Update for the Third Quarter of 2021
November 16, 2021 09:23 ET
|
BioCorRx Inc
ANAHEIM, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant
October 07, 2021 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th
September 29, 2021 12:16 ET
|
BioCorRx Inc
ANAHEIM, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Files Patent Application with USPTO for Naltrexone Implant
September 22, 2021 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
September 08, 2021 07:00 ET
|
BioCorRx Inc
SAN DIEGO, CA, and ANAHEIM, CA, Sept. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO)...
BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
September 01, 2021 08:30 ET
|
BioCorRx Inc
On track to commence the first-in-human clinical trial for BICX104 ANAHEIM, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
BioCorRx Provides Business Update for the Second Quarter of 2021
August 16, 2021 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Aug. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Welcomes Four Experts to Expanded Scientific Advisory Board
June 22, 2021 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, June 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of...